Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
出版年份 2019 全文链接
标题
Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
作者
关键词
-
出版物
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-05-23
DOI
10.1111/apt.15297
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver
- (2018) Hemant Shah et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set
- (2018) Christopher Ma et al. Clinical Gastroenterology and Hepatology
- Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review for Development of a Core Outcome Set
- (2018) Christopher Ma et al. Clinical Gastroenterology and Hepatology
- Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials
- (2018) Ferdinando D’Amico et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- 349 - BMS-986165 is a Highly Potent and Selective Allosteric Inhibitor of TYK2, Blocks Il-12, IL-23 and type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Inflammatory Bowel Disease
- (2018) Jenny H. Xie et al. GASTROENTEROLOGY
- 906 - Efficacy and Safety of Upadacitinib Maintenance Treatment for Moderate to Severe Crohn's Disease: Results from the Celest Study
- (2018) Julian Panes et al. GASTROENTEROLOGY
- Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention
- (2018) Jean-Frédéric Colombel INFLAMMATORY BOWEL DISEASES
- Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
- (2018) Kevin L Winthrop et al. INFLAMMATORY BOWEL DISEASES
- Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
- (2018) Bruce E Sands et al. Journal of Crohns & Colitis
- Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life
- (2018) Paschalis Paschos et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
- (2018) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Clinical significance of Janus Kinase inhibitor selectivity
- (2018) Ernest H Choy RHEUMATOLOGY
- JAK inhibition in inflammatory bowel disease
- (2017) Pablo Olivera et al. Expert Review of Clinical Immunology
- Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest
- (2017) William J. Sandborn et al. GASTROENTEROLOGY
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
- (2017) L.C.S. De Vries et al. Journal of Crohns & Colitis
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?
- (2017) Abhinav Vasudevan et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis
- (2016) Stefanos Bonovas et al. Clinical Gastroenterology and Hepatology
- Next generation of small molecules in inflammatory bowel disease
- (2016) Pablo Olivera et al. GUT
- Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
- (2016) Anthony L. Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Janus kinases in inflammatory bowel disease: Four kinases for multiple purposes
- (2016) René Galien Pharmacological Reports
- Loss of Response to Anti-TNFs: Definition, Epidemiology and Management
- (2016) Giulia Roda et al. Clinical and Translational Gastroenterology
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
- (2015) Himal Lal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tyrosine kinase-2 gene polymorphisms are associated with ulcerative colitis and Crohn's disease in Turkish Population
- (2015) Güray Can et al. Clinics and Research in Hepatology and Gastroenterology
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
- (2014) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease
- (2012) M. D. Long et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Biology and significance of the JAK/STAT signalling pathways
- (2012) Hiu Kiu et al. GROWTH FACTORS
- Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study
- (2012) Mirthe Emilie van der Valk et al. GUT
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing Response and Loss of Response to Biological Therapies in IBD
- (2011) Henit Yanai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Proteins Encoded in Genomic Regions Associated with Immune-Mediated Disease Physically Interact and Suggest Underlying Biology
- (2011) Elizabeth J. Rossin et al. PLoS Genetics
- Strong Evidence of a Combination Polymorphism of the Tyrosine Kinase 2 Gene and the Signal Transducer and Activator of Transcription 3 Gene as a DNA-Based Biomarker for Susceptibility to Crohn’s Disease in the Japanese Population
- (2009) Kayoko Sato et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares
- (2008) P. D. R. HIGGINS et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
- (2008) Jeffrey C Barrett et al. NATURE GENETICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now